Nine-month results of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular oedema: A retrospective analysis

Acta Ophthalmologica

Volumn 89, Issue 8, 2011, Pages 769-773

  Kook, Patricia E ^a   Maier, Mathias ^a   Schuster, Tibor ^b   Feucht, Nikolaus ^a   Lohmann, Chris P ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

bevacizumab; diabetic macular oedema; intravitreal injection; triamcinolone

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN A1C; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DIABETIC MACULAR EDEMA; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LASER COAGULATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; VISUAL ACUITY; VITRECTOMY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 82155166433     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01823.x     Document Type: Article

References (28)

1. Ahmadieh H, Ramezani A, Shoeibi N, et al., (2008): Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 247: 483-489. (Pubitemid 351447960)
2. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, &, Gardner TW, (1999): Vascular endothelial growth factor induces rapid phosophorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumours. J Biol Chem 274: 23463-23467.
3. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, &, Scaduto RC Jr, (2002): Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 80: 667-677. (Pubitemid 34809975)
4. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al., (2007): Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Results from the Pan-American Collaborative Retina Study Group at 6 month follow-up. Ophthalmology 114: 743-750. (Pubitemid 46483714)
5. Brooks HL Jr, Caballero S Jr, Newell CK, et al., (2004): Vitreous levels of vascular endothelial growth factor and stromal derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after injection of triamcinolone. Arch Ophthalmol 122: 1801-1807. (Pubitemid 39602140)
6. Chun DW, Heier JS, Topping TM, Duker JS, &, Bankert JM, (2006): A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113: 1706-1712. (Pubitemid 44442451)
7. Fang X, Sakaguchi H, Gomi F, et al., (2008): Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol 86: 800-805.
8. Fischer S, Renz D, Schaper W, &, Karliczek GF, (2001): In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol 411: 231-243. (Pubitemid 32119593)
9. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, &, Zhu M, (2006): Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113: 1533-1538. (Pubitemid 44292310)
10. Haritoglou C, Kook D, Neubauer A, et al., (2006): Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26: 999-1005. (Pubitemid 44973218)
11. Harris MI, (1998): Diabetes in America: epidemiology and scope of the problem. Diabetes Care 21 (Suppl. 3): C11-C14. (Pubitemid 28545944)
12. International Diabetes Federation (2007): Diabetes prevalence. Available from:.
13. Jonas JB, Akkoyun I, Kreissig I, &, Degenring RF, (2005a): Diffuse diabetic macular edema treated by intravitreal triamcinolone acetonide. A comparative non-randomised study. Br J Ophthalmol 89: 321-326. (Pubitemid 40327617)
14. Jonas JB, Martus P, Degenring RF, Kreissig I, &, Akkoyun I, (2005b): Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol 123: 1338-1343. (Pubitemid 41429733)
15. Klein R, Klein BE, &, Moss SE, (1984): Visual impairment in diabetes. Ophthalmology 91: 1-9. (Pubitemid 14184710)
16. Lecleire-Collet A, Offret O, Gaucher D, Audren F, Haouchine B, &, Massin P, (2007): Full-thickness macular hole in a patient with diabetic cystoid macular oedema treated by intravitreal triamcinolone injections. Acta Ophthalmol 85: 795-798. (Pubitemid 47616800)
17. Lee CM, &, Olk RJ, (1991): Modified grid laser photocoagulation for diffuse diabetic macular edema. Longterm visual results. Ophthalmology 98: 1594-1602.
18. Margolis R, Singh RP, Bhatnagar P, &, Kaiser PK, (2008): Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema. Acta Ophthalmol 86: 105-110. (Pubitemid 351515705)
19. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, &, Jorge R, (2007): Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular edema (IBEME Study). Br J Ophthalmol 92: 76-80.
20. Schmid KE, Neumaier-Ammerer B, Stolba U, &, Binder S, et al., (2006): Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (Hba1c). Graefes Arch Clin Exp Ophthalmol 244: 1446-1452. (Pubitemid 44741256)
21. Soheilian M, Ramezani A, Bijanzadeh B, et al., (2007): Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 27: 1187-1195. (Pubitemid 350211523)
22. Soliman W, Sander B, Hasler PW, &, Larsen M, (2008a): Correlation between intraretinal changes in diabetic macular oedema seen in fluorescein angiography and optical coherence tomography. Acta Ophthalmol 86: 34-39. (Pubitemid 351512467)
23. Soliman W, Vinten M, Sander B, Soliman KA, Yehya S, Rahman MS, &, Larsen M, (2008b): Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol 86: 365-371.
24. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, &, Adamis AP, (1996): Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103: 1820-1823.
25. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, &, Lutty GA, (2002): Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133: 373-385. (Pubitemid 34171588)
26. Vinten M, Larsen M, Lund-Andersen H, Sander B, &, La Cour M, (2007): Short-term effects of intravitreal triamcinolone on retinal vascular leakage and trunk vessel diameters in diabetic macular oedema. Acta Ophthalmol 85: 21-26. (Pubitemid 46140151)
27. Yang JC, Haworth L, Sherry RM, et al., (2003): Randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic colorectal cancer. N Engl J Med 349: 427-431.
28. Yanyali A, Aytug B, Horozoglu F, &, Nohutcu AF, (2007): Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 144: 124-126. (Pubitemid 46963178)